Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

InflaRx (NASDAQ:IFRX – Free Report) had its target price hoisted by Guggenheim from $7.00 to $10.00 in a report published on Wednesday morning, Ratings reports. The brokerage currently has a buy ...